Bristol Myers rises, AbbVie sinks

AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say
AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said.
AbbVie tumbles after new schizophrenia drug fails trials
AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet their primary goal, a blow to the company’s $8.7 billion acquisition of Cerevel Therapeutics earlier this year.
Bristol Myers rises, AbbVie sinks after schizophrenia trials miss targets
Shares of AbbVie (ABBV) are sinking on Monday after the company said two mid-stage trials of its investigative treatment for adults with
Bristol Myers Squibb’s stock soars after rival AbbVie reports disappointing schizophrenia-drug trial
Bristol Myers Squibb Co. shares surged on Monday after rival AbbVie Inc. reported disappointing results from the trial of a new schizophrenia drug. Bristol Myers’s stock was up more than 11% in afternoon trading,
AbbVie Stock Sinks After Schizophrenia Drug Trials Disappoint
Key Takeaways Shares of AbbVie plummeted Monday after the company said its schizophrenia drug Emraclidine missed key goals in a pair of trials.Abbvie said the trials did not show a statistically significant improvement in symptoms compared with the placebo group at week 6.
STAT6h
AbbVie’s stumble, Amgen’s tumble and more election fallout
On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...
BioPharma Dive3d
On Wall Street, ‘flat out’ failure of AbbVie schizophrenia drug leaves analysts stunned
Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...
AbbVie stock drops 12% on schizophrenia drug setback: should you buy the dip?
AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...
Irish Independent on MSN40m
Profits drop at Botox plant in Westport as revenues down by 4pc
Pre-tax profits at AbbVie’s global production facility for Botox, in Westport, last year declined by 27pc to $1.1bn (€1.04bn). New accounts filed by Allergan Pharmaceuticals Ireland UC show that the ...
Hosted on MSN10h
Profits fall by 27% at Abbvie's Botox plant at Westport
Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...
My Favorite Dividend King to Buy in November
However, arguably the next best thing is for a company to belong to the elite group known as Dividend Kings. To qualify, a ...
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...
Truist Financial Sticks to Its Buy Rating for AbbVie (ABBV)
In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on AbbVie (ABBV – Research Report). The ...
Robert Bruce's Strategic Moves in Q3 2024: Spotlight on AerCap Holdings NV
Insight into the Investment Shifts of Bruce & Co. Robert Bruce (Trades, Portfolio), the seasoned investor behind Bruce & Co, ...
AbbVie's Emraclidine For Schizophrenia 'Surprisingly Disappoints,' Analyst Says Pipeline Is Underappreciated
AbbVie's emraclidine trials for schizophrenia fail, leading to stock decline, but analysts maintain confidence in the company ...
Aldeyra's FDA Resubmission And AbbVie Option Revitalize Reproxalap's Prospects
Aldeyra received an FDA CRL for reproxalap, necessitating an additional study for DED approval. Read why I continue to rate ...